FDA finalises guidance on manufacturing changes to biosimilar drugs

The Food and Drug Administration has finalised guidance telling makers of biosimilar medicines what information they should submit when they change how an already-approved product is manufactured. The notice announcing the guidance was published in the Federal Register on 13 October 2026 [s1].

Biosimilars are biological medicines shown to be highly similar to, and to have no clinically meaningful differences from, an already-licensed "reference" biologic. They are licensed under section 351(k) of the Public Health Service Act, and are a principal route to competition — and lower prices — for expensive biologic drugs once the original's exclusivity has lapsed. Because biologics are manufactured in living systems, even routine changes to a production process can affect the product, which is why the agency reviews such changes after approval.

What the guidance covers

The document is written as answers to "commonly asked questions from applicants and other interested parties regarding postapproval manufacturing changes made to biosimilar and interchangeable biosimilar products" [s1]. Its purpose, the FDA says, is to inform applicants "of the nature and type of information, for different reporting categories, that applicants should provide to support manufacturing changes to licensed biosimilar and licensed interchangeable biosimilar products" [s1].

Reporting categories are the tiers that determine how a manufacturer must notify the agency of a change and how far in advance — a framework that sorts changes by their potential to affect a product's safety or effectiveness. The guidance is meant to clarify what evidence supports a change in each tier. The FDA says its recommendations are intended to be consistent with the principles in the long-standing international comparability guidance known as ICH Q5E, which addresses biological products subject to changes in their manufacturing process [s1].

The guidance is a question-and-answer companion to the agency's broader biosimilar guidance. The FDA notes that it previously published a set of questions and answers on biosimilar development and the Biologics Price Competition and Innovation Act, and that the new document extends that line of guidance into the postapproval stage [s1].

A user-fee commitment

The FDA ties the guidance to a specific obligation. It says it is publishing the document "to fulfill the commitment made in the 2022 reauthorization of the Biosimilar User Fee Act," the agreement under which biosimilar developers pay fees to fund the agency's review programme in exchange for defined performance goals [s1]. That reauthorisation covers fiscal years 2023 through 2027 [s1]. Producing written guidance of this kind is among the deliverables the agency negotiated as part of the programme, which links industry funding to the agency's commitments on predictability and timeliness.

The final version follows a draft of the same title that the FDA issued on 23 July 2024 [s1][s2]. Finalising a guidance after a public draft is the agency's standard sequence: it proposes recommendations, takes comment, and then issues a settled version that represents its current thinking. The user-fee programme that frames the document works on the same logic of exchange — developers fund a portion of the agency's review capacity, and in return the FDA commits to defined performance goals and to producing policy documents, like this one, that make its expectations explicit.

What the guidance is and is not

Guidance documents do not carry the force of law. They describe the agency's current recommendations and are not binding on either the FDA or industry; a manufacturer may use an alternative approach that satisfies the applicable statutes and regulations. The value of a document like this is predictability — it narrows the uncertainty a company faces about what the agency will expect when a proposed change lands on a reviewer's desk.

That predictability is the policy point. Clearer expectations around postapproval manufacturing changes can lower the regulatory friction of maintaining a biosimilar on the market, which bears on whether firms stay in a product class long enough for competition to hold prices down. The guidance does not change the standard a biosimilar must meet, nor the underlying licensing pathway; it addresses the narrower, practical question of what to file, and when, after a product is already approved [s1].

For now, the concrete facts are that the guidance is final, that it was issued on 13 October 2026 to satisfy a 2022 user-fee commitment running through fiscal 2027, and that it finalises a draft first published in July 2024 [s1][s2]. The agency notes that, as with any guidance, comments may be submitted at any time [s1].